WALTHAM, Mass., March 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing ...

Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance ...

Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com .

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report)’s stock price rose 6.6% during trading on Friday after the company announced better than expected quarterly earnings. The company ...

Investors considering a purchase of Spyre Therapeutics Inc (Symbol ... Collecting that bid as the premium represents a 6.8% return against the $12.50 commitment, or a 13.5% annualized rate ...

Wolfe Research initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $27 price target The company is an early stage biotech with Phase 1 readouts in 2025, offering a ...

Even though spring has made her grand entrance, there will inevitably be days when getting your steps in outside isn’t ...

The Xiaomi Pad 7 Pro may be an iPad clone, but with solid performance and helpful accessories, that's a good thing.

SUPER ABSORBENT CORE - Our ultra premium, pillowy pad provides ultimate comfort and protection. Prevents overflowing and leaks and sustains freshness all day to keep you feeling drier, longer.

Spyre Therapeutics stock opened at $18.40 on Tuesday. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -2.46 and a beta of 2.98. The firm has a 50 day simple ...

MSRP: $89.99 non-insulated/$99.99 insulated Sequoia Self-Inflating Sleeping Pad Self-inflating 78" x 26.8" premium mattress pad with 3" die-cut memory foam for added comfort that feels like a real ...